பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் உட் தென்மேற்கு மருத்துவ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் உட் தென்மேற்கு மருத்துவ மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் உட் தென்மேற்கு மருத்துவ மையம் Today - Breaking & Trending Today

More Evidence Once-Weekly Semaglutide Injection Helps People With Diabetes Lose Weight


More Evidence Once-Weekly Semaglutide Injection Helps People With Diabetes Lose Weight
Sold in a lower dose under the brand names Ozempic and Rybelsus to treat type 2 diabetes, semaglutide may also be safe and effective for chronic weight management, a new study suggests.
March 8, 2021
Semaglutide is sold as the injectable Ozempic, which is a GLP1 agonist that mimics the feel-full hormone, possibly aiding weight loss.
Everyday Health
A higher-dose version of an injected drug approved for type 2 diabetes may help many people with this condition who also have overweight or obesity lose at least 5 percent of their body weight a threshold that can help reduce the risk of many weight-related chronic health problems. ....

United States , New York , Baton Rouge , University Of Texas Southwestern Medical Center , Frank Greenway , Ildiko Lingvay , Beverly Tchang , Robert Kushner , Pennington Biomedical Research Center , University Of Texas Ut Southwestern Medical Center , Drug Administration , Northwestern University Feinberg School Of Medicine , Novo Nordisk , Medical Center , Can Weight Loss Surgery Reverse Type , May Boost Effects , Exercise Changes , Increase Weight , Prediabetes Diet Everyone Should , Weight Loss , New England Journal , Current Obesity , Loss Tends , Northwestern University Feinberg School , Term Weight Management , Weill Cornell Medicine ,

Report on Research Compliance Volume 18, Number 2. In This Month's E-News: February 2021 | Health Care Compliance Association (HCCA)



A National Science Foundation (NSF) Office of Inspector General (OIG) audit of five Established Program to Stimulate Competitive Research (EPSCoR) awards to the University of Kansas Center for Research (KUCR) questioned $1,550,054 in direct and indirect costs. The largest amount, $625,532, stemmed from what auditors called “inappropriately retained indirect costs.” KUCR’s charges to NSF “exceeded costs paid to its subrecipients,” auditors said in the Jan. 7 report. Subrecipients, under a 2016 agreement, “billed KUCR for indirect costs on EPSCoR awards at rates that were 8 percentage points lower than their formal negotiated indirect cost rates. KUCR paid subrecipients at the lower rates, but it charged the EPSCoR awards for allowable indirect costs at the full, negotiated indirect cost rates and retained the remainder.” Auditors said NSF was not aware of this arrangement. “KUCR agreed to end the practice,” according to the report, but disagreed that its ....

United States , University Of Texas Southwestern Medical Center , Lisett Raventos , Beth Bloom , Yvelice Villaman Bencosme , University Of Kansas Center , Department Of Justice , Texasam University , Office Of Inspector , A National Science Foundation , Us District Court , Public Health Service , University Of Texas Ut Southwestern Medical Center , Virginia Murchison Linthicum Scholar In Medical Research , Program To Stimulate Competitive Research Epsco , Haskell Indian Nations University , Health Care Compliance Association , Office Of Research Integrity , National Science Foundation , Inspector General , Established Program , Stimulate Competitive Research , Kansas Center , Villaman Bencosme , Unlimited Medical , Court Judge Beth Bloom ,

Young but ambitious Taysha lays out $76M for commercial gene therapy plant


RA Session II, founder, president and CEO of Taysha (Taysha Gene Therapies)
Taysha Gene Therapies hit the ground running when it launched this spring, cruising through a $95 million series B straight to a $100 million IPO in September. With its lead program now approved for human trials in Canada, the company is sketching out plans for what it hopes will become its prime commercial manufacturing site.
Taysha leased a 187,000-square-foot commercial-scale manufacturing facility in Durham, North Carolina, planning to invest $75 million to kit out the facility for preclinical, clinical and commercial gene therapy production. It’s also due to receive up to $9.4 million in state and local incentives for the project, Taysha said in a release.  ....

North Carolina , United States , Suyash Prasad , Fred Porter , Queen University , University Of Texas Ut Southwestern Medical Center , Health Canada , Taysha Gene Therapies , Optimal Scale Up , Tech Transfer , Moral Small , Southwestern Medical Center , வடக்கு கரோலினா , ஒன்றுபட்டது மாநிலங்களில் , சுயஷ் பிரசாத் , ஃப்ரெட் போர்டர் , ராணி பல்கலைக்கழகம் , பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் உட் தென்மேற்கு மருத்துவ மையம் , ஆரோக்கியம் கனடா , தாய்ஷ்ா கீந் சிகிச்சைகள் , உகந்த அளவு மேலே , தொழில்நுட்பம் பரிமாற்றம் , வாய்வழி சிறிய , தென்மேற்கு மருத்துவ மையம் ,